Health & Fitness
Health and Fitness
Health and Fitness
Wed, April 11, 2012Tue, April 10, 2012Mon, April 9, 2012Fri, April 6, 2012Thu, April 5, 2012Wed, April 4, 2012Tue, April 3, 2012Mon, April 2, 2012Sun, April 1, 2012Sat, March 31, 2012Fri, March 30, 2012Thu, March 29, 2012Wed, March 28, 2012Tue, March 27, 2012Boston Therapeutics Corporate Update
Published in Health and Fitness on Monday, April 2nd 2012 at 13:06 GMT by Market Wire
April 02, 2012 15:57 ET
Boston Therapeutics Corporate Update
MANCHESTER, NH--(Marketwire - Apr 2, 2012) - Boston Therapeutics Inc. (
Boston Therapeutics submitted SUGARDOWN® structure and function claims to the US Food and Drug Administration as a novel non-systemic chewable dietary supplement that supports glycemic control and digestive health.
Following the submission to the US Food and Drug Administration, Boston Therapeutics licensed exclusive rights to commercialize SUGARDOWN® for blood sugar management in China to Advance Pharmaceutical Co. Ltd.
Last year Boston Therapeutics also completed a human clinical study with SUGARDOWN® at University of Sydney, Australia and initiated a Phase 2 Clinical Trial of PAZ320 in Type 2 Diabetes at Dartmouth-Hitchcock Medical Center, New Hampshire.
A few months ago, Boston Therapeutics received its first purchase order for sales of SUGARDOWN® in Italy and announced clinical study safety results with SUGARDOWN® at University of Sydney in Australia.
Boston Therapeutics recently received regulatory clearance to be listed on the OTC Bulletin Board and was quoted under the ticker BTHE.OB
About Boston Therapeutics, Inc.
Boston Therapeutics, headquartered in Manchester, NH, is a leader in the field of glyco-pathology, a specialized field involving understanding the importance of carbohydrates in biochemistry and progression of diseases. The Company's initial product pipeline is focused on developing and commercializing therapeutic molecules for diabetes: PAZ320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose excursion; SUGARDOWN®, a non-systemic chewable complex carbohydrate dietary supplement designed to moderate post-meal blood glucose; and IPOXYN™, a systemic, injectable complex carbohydrate-based oxygen therapeutic for limb ischemia.
Additional information is available at [ www.bostonti.com ] and [ www.sugardown.com ]
For more information about Boston Therapeutics, its lead OTC product, SUGARDOWN®, PAZ320, or Ipoxyn™, please visit [ www.bostonti.com ] and [ www.sugardown.com ]
